Author: [email protected]

Ironwood Pharmaceuticals to Host Third Quarter 2017 Investor Update Call

On October 19, 2017 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) reported that it will host its third quarter 2017 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 2, 2017 (Press release, Ironwood Pharmaceuticals, OCT 19, 2017, View Source [SID1234521041]). Individuals interested in participating in the call should dial (877) 643-7155 (U.S. and Canada) or (914) 495-8552 (international) using conference ID number 1071726. To access the webcast, please visit the Investors section of Ironwood’s website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The call will be available for replay via telephone starting November 2, 2017 at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on November 9, 2017. To listen to the replay, dial (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international) using conference ID number 1071726. The archived webcast will be available on Ironwood’s website for 14 days beginning approximately one hour after the call has completed.

10-Q/A [Amend] – Quarterly report [Sections 13 or 15(d)]

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Five Prime to Present Preclinical Data on FPT155 at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

On October 18, 2017 Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, reported that it will feature new preclinical data on FPT155, its novel therapeutic CD80-Fc fusion protein, in a poster presentation at the 2017 AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) (Press release, Five Prime Therapeutics, OCT 18, 2017, View Source [SID1234521014]). The conference is scheduled to take place October 26-30, 2017, in Philadelphia, and abstracts may now be viewed online through the itinerary planner.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Know more, wherever you are:
Latest on AACR (Free AACR Whitepaper)-NCI-EORTC through 1stOncology, book your free 1stOncology demo here.

Abstract Number and Title: B005 – "FPT155, a novel therapeutic CD80-Fc fusion protein, with potent anti-tumor activity in preclinical models"
Session Title: Session PO.B01 – Immune Modulators
Session Date and Time: Sunday, October 29, 2017, 12:30 – 4:00 PM
Location: Hall E, Philadelphia Convention Center

Exelixis to Release Third Quarter 2017 Financial Results on Wednesday, November 1, 2017

On October 18, 2017 Exelixis, Inc. (NASDAQ:EXEL) reported that its third quarter 2017 financial results will be released on Wednesday, November 1, 2017 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call to discuss the results and provide a general business update (Press release, Exelixis, OCT 18, 2017, View Source;p=RssLanding&cat=news&id=2309609 [SID1234521013]). The conference call will be accessible via the Internet from the company’s website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Know more, wherever you are:
Latest on Exelixis Cancer Pipeline, book your free 1stOncology demo here.

To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call (855) 793-2457 (domestic) or (631) 485-4921 (international) and provide the conference call passcode 96645455 to join by phone.

A telephone replay will be available until 8:00 p.m. EDT on November 3, 2017. Access numbers for the telephone replay are: 855-859-2056 (domestic) and 404-537-3406 (international); the passcode is 96645455. A webcast replay will also be archived on www.exelixis.com for one year.

Corvus Pharmaceuticals to Present Data on Lead Checkpoint Inhibitor CPI-444 at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

On October 18, 2017 Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, reported that it will present data on lead checkpoint inhibitor CPI-444 from its ongoing Phase 1/1b study in an oral session at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 32ND Annual Meeting, which is taking place November 8-12 in National Harbor, Maryland. Following are the details for the oral presentation (Press release, Corvus Pharmaceuticals, OCT 18, 2017, View Source;p=RssLanding&cat=news&id=2309621 [SID1234521012]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Know more, wherever you are:
Latest on SITC (Free SITC Whitepaper) through 1stOncology, book your free 1stOncology demo here.

ORAL PRESENTATION

TITLE: Clinical Activity of Adenosine A2a Receptor (A2aR) Inhibitor CPI-444 is Associated with Tumor Expression of Adenosine Pathway Genes and Tumor Immune Modulation
PRESENTER: Jason J. Luke, M.D., FACP, Assistant Professor of Medicine, University of Chicago Medicine
SESSION: Clinical Trials: Novel Combinations
PRESENTATION DATE AND TIME: November 11, 2017, 5:45 – 6:00 p.m. EST